Advanced ovarian carcinoma, small cell & non-small cell lung cancer, squamous cell carcinoma of the head & neck, advanced transitional cell carcinoma of the bladder, carcinoma of the cervix. In combination w/ other chemotherapeutic agent eg, paclitaxel in 1st line therapy of ovarian carcinoma & non small cell lung cancer.
IVPreviously untreated adult w/ normal kidney function 400 mg/m2 as a single short term infusion over 15-60 min. Not to be repeated until 4 wk have elapsed. Patient w/ risk factors eg, previous myelosuppressive therapy & debilitated status May need to reduce initial dose by 20-25%.Patient w/ impaired renal function CrCl 41-59 mL/min 250 mg/m2, 16-40 mL/min 200 mg/m2.
Hypersensitivity to carboplatin, other platinum-containing compd or mannitol. Severe myelosuppression, bleeding tumors. Pre-existing severe renal impairment. Women of child bearing potential should use adequate contraception. Not recommended in pregnancy. Not advised during breast feeding.
Risk of more severe & prolonged myelosuppression especially thrombocytopenia in patients w/ abnormal renal function or receiving nephrotoxic drugs. More likely to have prolonged & more severe toxicity in patients who have received extensive prior treatment, debilitated status & more advanced age. Assess renal function & peripheral blood counts (including platelets, WBC & Hb) prior to, during & following treatment. Potentially mutagenic & patients should use effective contraception for an adequate time after discontinuing treatment. Discontinue treatment if blood cell counts <2,000 cells/mm3 or platelets <50,000 cells/mm3 after 5-6 wk until bone marrow recovery is evident. Regularly perform neurological evaluations & hearing assessment. Al-containing equipment should not be used.
Formation of block precipitate w/ Al. Needles, syringes, catheters or IV administration sets containing Al should not be used for prep or administration. May increase or exacerbate toxicity including changes in renal clearance w/ nephrotoxic drugs. Combination therapy w/ other myelosuppressive drugs may cause consideration to alter the dose or timing of therapy.
Sign Out
